Managing Immune-Related Toxicities with Frontline RCC Therapies
Expert panelists discuss the importance of rapid improvement within 24-72 hours with steroids for managing unpredictable immune-related toxicities that can occur with frontline IO-IO or IO-TKI regimens for patients with RCC.
EP: 1.Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC
EP: 2.Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC
EP: 3.Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC
EP: 4.Frontline Treatment Approaches for Advanced Clear Cell RCC
EP: 5.Treatment Decisions for Favorable Risk RCC
Now Viewing
EP: 6.Managing Immune-Related Toxicities with Frontline RCC Therapies
EP: 7.Treating Patients with RCC and Brain, Liver, or Bone Metastases
EP: 8.Frontline Therapy for Patients With Non-Clear Cell RCC
EP: 9.Non-Clear Cell RCC: Key Learnings and Future Research Directions
Recent Videos
Related Content
